Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Operating Expenses:
Research and development	$ 1,004,454	$ 528,355	$ 3,250,109	$ 3,458,657
General and administrative	438,359	829,406	1,828,675	2,693,293
Total Operating Expenses	1,442,813	1,357,761	5,078,784	6,151,950
Total Operating Loss	(1,442,813)	(1,357,761)	(5,078,784)	(6,151,950)
Other Income/(Expense):
Gain on settlement of lawsuits			675,000	825,000
Research and development tax credit	(826)		82,115	42,685
Investment and interest income	1,140	4,931	23,045	16,656
Interest expense	(377,576)	(256,173)	(1,068,600)	(697,214)
Net Loss	$ (1,820,075)	$ (1,609,003)	$ (5,367,224)	$ (5,964,823)
Basic and Diluted Loss Per Common Share	$ (0.00)	$ (0.00)	$ (0.01)	$ (0.02)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	385,817,485	383,256,742	385,726,721	380,754,529